Precigen (PGEN) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precigen (PGEN) has outperformed Taysha Gene Therapies (TSHA) over the past year, gaining 136.0% versus a loss of 12.5%. Over five years, PGEN leads with a +63.4% price change compared with -75.2% for TSHA. Precigen is the larger company by market cap ($2.72 billion vs $1.44 billion), about 1.9 times the size.
Taysha Gene Therapies converts more of its revenue into profit, with a net margin of -1115.3% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PGEN | TSHA |
|---|---|---|
| Share price | $7.60 | $4.43 |
| Market cap | $2.72B | $1.44B |
| 1-day change | +0.80% | 0.00% |
| YTD return | +81.82% | -19.45% |
| 1-year return | +136.02% | -12.45% |
| 5-year return | +63.44% | -75.22% |
| EPS (TTM) | $-1.04 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.68M | $9.77M |
| Revenue growth (YoY) | +146.73% | +17.28% |
| Net income (latest FY) | $-250.64M | $-109.00M |
| Operating margin | -1141.13% | -1130.65% |
| Net margin | -2588.21% | -1115.27% |
| 52-week high | $8.98 | $7.30 |
| 52-week low | $2.99 | $3.69 |
| Distance from 52-week high | -15.37% | -39.32% |
| Analyst consensus | buy | none |
| Avg. price target upside | +79.61% | +193.45% |
| Average volume | 5.03M | 3.28M |
| Shares outstanding | 358.04M | 325.83M |
| Employees | 160 | 99 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed TSHA by 148.5 percentage points over the past year.
- Taysha Gene Therapies is more profitable, keeping -1115.3 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs +17.28%).
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Healthcare · Biotechnology · 160 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Healthcare · Biotechnology · 99 employees
PGEN vs TSHA FAQ
Which is bigger, Precigen or Taysha Gene Therapies?
Precigen (PGEN) is larger, with a market capitalization of $2.72B compared with $1.44B for Taysha Gene Therapies (TSHA).
Which stock has performed better over the past year, PGEN or TSHA?
PGEN returned +136.02% over the past 12 months, compared with -12.45% for TSHA (price return, excluding dividends). Past performance does not predict future results.
Are Precigen and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.